Praxis Precision Medicines
PRAX

$61.51

2.4%

Market Cap: $1.09B

About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Employees: 82

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 15 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

147% more capital invested

Capital invested by funds: $977M [Q1] → $2.41B (+$1.44B) [Q2]

58% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 26

3% more funds holding

Funds holding: 110 [Q1] → 113 (+3) [Q2]

8% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 36

7% less call options, than puts

Call options by funds: $35.4M | Put options by funds: $38.1M

13.26% less ownership

Funds ownership: 120.96% [Q1] → 107.7% (-13.26%) [Q2]

44% less funds holding in top 10

Funds holding in top 10: 9 [Q1] → 5 (-4) [Q2]

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$48

22%

downside

Avg. target

$143

132%

upside

High target

$270

339%

upside

15 analyst ratings

14 positive

93%

1 neutral

7%

0 negative

0%

HC Wainwright & Co. Douglas Tsao 56% 1-year accuracy 79 / 142 met price target	95%upside $120	Buy Reiterated	10 Sept 2024
Needham Ami Fadia 55% 1-year accuracy 71 / 129 met price target	145%upside $151	Buy Reiterated	5 Sept 2024
Oppenheimer Francois Brisebois 60% 1-year accuracy 18 / 30 met price target	132%upside $143	Outperform Reiterated	4 Sept 2024
Needham Ami Fadia 55% 1-year accuracy 71 / 129 met price target	145%upside $151	Buy Maintained	4 Sept 2024
HC Wainwright & Co. Douglas Tsao 56% 1-year accuracy 79 / 142 met price target	95%upside $120	Buy Reiterated	3 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about PRAX published over the past 30 days

Zacks Investment Research

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients.

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Zacks Investment Research

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?

Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Praxis Precision Medicines, Inc. PRAX reported a loss for the second quarter on Tuesday.

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief Financial Officer Daniel Ferry - Investor Relations, Life Science Advisors Conference Call Participants Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Ritu Baral - TD Cowan Joel Beatty - Baird Ami Fadia - Needham Douglas Tsao - HC Wainwright & Co Kambiz Yazdi - Jeffries Operator Good day, thank you for standing by. Welcome to the Praxis Precision Medicines' Second Quarter 2024 Corporate Update Conference Call.

Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript

Zacks Investment Research

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates

Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares to loss of $7.35 per share a year ago.

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the second quarter ended June 30, 2024, before the financial markets open on Tuesday, August 13, 2024.

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

Zacks Investment Research

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

See News Rankings